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AbstrAct
ObjeCtive
To determine whether intensive combinations of 
synthetic disease modifying drugs can achieve 
similar clinical benefits at lower costs to high cost 
biologics such as tumour necrosis factor inhibitors in 
patients with active rheumatoid arthritis resistant to 
initial methotrexate and other synthetic disease 
modifying drugs.
Design
Open label pragmatic randomised multicentre two arm 
non-inferiority trial over 12 months.
setting
24 rheumatology clinics in England.
PartiCiPants
Patients with rheumatoid arthritis who were eligible for 
treatment with tumour necrosis factor inhibitors 
according to current English guidance were randomised 
to either the tumour necrosis factor inhibitor strategy or 
the combined disease modifying drug strategy.
interventiOns
Biologic strategy: start tumour necrosis factor 
inhibitor; second biologic in six month for non-
responders. Alternative strategy: start combination of 
disease modifying drugs; start tumour necrosis factor 
inhibitors after six months in non-responders.
Main OutCOMe Measure
Primary outcome: reduction in disability at 12 months 
measured with patient recorded heath assessment 
questionnaire (range 0.00–3.00) with a 0.22 
non-inferiority margin for combination treatment 
versus the biologic strategy. Secondary outcomes: 
quality of life, joint damage, disease activity, adverse 
events, and costs. Intention to treat analysis used 
multiple imputation methods for missing data.
results
432 patients were screened: 107 were randomised to 
tumour necrosis factor inhibitors and 101 started taking; 
107 were randomised to the combined drug strategy and 
104 started taking the drugs. Initial assessments were 
similar; 16 patients were lost to follow-up (seven with 
the tumour necrosis factor inhibitor strategy, nine with 
the combined drug strategy); 42 discontinued the 
intervention but were followed-up (19 and 23, 
respectively). The primary outcome showed mean falls 
in scores on the health assessment questionnaire of 
−0.30 with the tumour necrosis factor inhibitor strategy 
and −0.45 with the alternative combined drug strategy. 
The difference between groups in unadjusted linear 
regression analysis favoured the alternative strategy of 
combined drugs. The mean difference was −0.14, and 
the 95% confidence interval (−0.29 to 0.01) was below 
the prespecified non-inferiority boundary of 0.22. 
Improvements at 12 months in secondary outcomes, 
including quality of life and erosive progression, were 
similar with both strategies. Initial reductions in disease 
activity were greater with the biologic strategy, but these 
differences did not persist beyond six months. 
Remission was seen in 72 patients (44 with biologic 
strategy; 36 with alternative strategy); 28 patients had 
serious adverse events (18 and 10, respectively); six and 
10 patients, respectively, stopped treatment because of 
toxicity. The alternative strategy reduced health and 
social care costs per patient by £3615 (€4930, $5585) 
for months 0–6 and £1930 for months 6–12.
COnClusiOns
In patients with active rheumatoid arthritis who meet 
English criteria for biologics an alternative strategy 
with combinations of intensive synthetic disease 
modifying drugs gives non-inferior outcomes to 
treatment with tumour necrosis factor inhibitors. 
Costs are reduced substantially.
trial registratiOn
ISRCTN 37438295.
Introduction
Tumour necrosis factor inhibitors, the first biologics 
for rheumatoid arthritis, have changed specialist 
WhAt Is AlreAdy knoWn on thIs topIc
Placebo controlled trials have shown that tumour necrosis factor inhibitors are 
effective in patients with active rheumatoid arthritis, and some economic models 
justify use when methotrexate does not work. Despite their high costs, their use 
has continually grown, and by 2012 international spending exceeded £15bn 
(€20.5bn, $23bn) a year
A combination of synthetic disease modifying drugs is an alternative cheaper and 
effective strategy in active rheumatoid arthritis
WhAt thIs study Adds
Patients with active rheumatoid arthritis eligible for biologic treatments according 
to current English guidance achieve non-inferior benefits in disability, with no 
demonstrable difference in quality of life or prevention of joint damage, with 
combined synthetic disease modifying drugs or tumour necrosis factor inhibitors
As combinations of synthetic disease modifying drugs cost less they should be 
considered when monotherapy with disease modifying drugs is not successful
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 management.1 Placebo controlled trials in patients 
with active rheumatoid arthritis defined their efficacy.2 
Long term observational studies confirmed their rela-
tive safety.3 Economic modelling used placebo con-
trolled trials to justify their use in patients with active 
rheumatoid arthritis who were resistant to methotrex-
ate.4 European and North American expert groups pro-
vided international guidance on their use in 
rheumatoid arthritis.5 6 English guidance from the 
National Institute for Health and Care Excellence 
(NICE) recommends starting them in patients with 
persistent active rheumatoid arthritis that is resistant 
to methotrexate and one other synthetic disease mod-
ifying drug7 and continuing them as long as the 
patients maintain good responses.
Tumour necrosis factor inhibitors are expensive. By 
2012 international spending exceeded £15bn (€20.5bn, 
$23bn) a year. Guidance for their use is driven by results 
of placebo controlled trials in rheumatoid arthritis 
sponsored by manufacturers. Few trials have compared 
them with active non-biological treatments,8 9 even 
though lower cost strategies, such as combinations of 
synthetic disease modifying drugs, are effective.10–13 
England spends over £600 m (€820 m, $926 m) a year 
on tumour necrosis factor inhibitors, which has a sub-
stantial impact on the National Health Service’s budget. 
Healthcare commissioners would prefer lower cost 
alternatives provided patients were not disadvantaged.
We evaluated this possibility by testing the hypothe-
sis that a lower cost strategy of combinations of syn-
thetic disease modifying drugs achieves outcomes that 
are not inferior and costs substantially less.  
Methods
Design
The TACIT (tumour necrosis factor inhibitors against 
combination intensive therapy) trial was an open label 
pragmatic randomised two arm non-inferiority trial car-
ried out over 12 months in multiple centres.
Participants
Patients were recruited from 24 rheumatology clinics in 
England. We included men and women aged over 18 
with disease durations over 12 months who met the 1987 
criteria for classification of rheumatoid arthritis and 
NICE criteria for starting biologics in England. The NICE 
criteria comprise disease activity score for 28 joints >5.1 
twice over one month apart after treatment with metho-
trexate and one other disease modifying drug.7 We 
excluded patients who unable or unwilling to give 
informed consent, had not had successful results with 
or had contraindications to all combinations of disease 
modifying drugs (including possible pregnancy), had 
contraindications to tumour necrosis factor inhibitors, 
had serious inter-current illness, or were taking high 
dose corticosteroids (>10 mg prednisolone).
interventions
The trial compared two treatment strategies in patients 
who completed local screening procedures for treat-
ment with tumour necrosis factor inhibitors, including 
tuberculosis screening. Safety monitoring followed 
national guidance. Treatment was guided by monthly 
changes in disease activity scores for 28 joints. The box 
outlines the tumour necrosis factor inhibitor strategy, 
which replicated NICE guidance when the trial started, 
and the combined disease modifying drug strategy. 
Treatments used as required at standard doses included 
non-opiate analgesics, non-steroidal anti-inflammatory 
drugs, folic acid (5 mg/week) with methotrexate, bone 
protection (such as alendronate and calcium/vitamin D) 
with glucocorticoids, and intra-articular steroids.
Primary outcome
The primary outcome was the score on the health 
assessment questionnaire at 12 months.14 Scores were 
measured initially at baseline and at six and 12 months. 
Trials of disease modifying drugs15 and biologics16 have 
shown that this patient assessed outcome is sensitive to 
change. Its performance is equal to disease activity 
measures like joint counts. Changes in health assess-
ment questionnaire scores influenced NICE’s decisions 
on biologics. It involves questions across eight domains: 
dressing and grooming, getting up, eating, walking, 
hygiene, reach, grip, and chores or activities. There are 
four possible answers: 0=without any difficulty; 1=with 
some difficulty; 2=with much difficulty; and 3=unable 
to do. The sum of the highest score per domain is 
divided by eight. The total score ranges from 0 to 3 
(0=best; 3=worst) in 0.125 increments.
Secondary outcomes
Every six months we assessed quality of life, erosive 
damage, and economics. Assessments comprised the 
EuroQol 5-dimension scale (EQ5D-3L), medical out-
comes study short form 36 (SF-36), and radiographs of 
the hands (including wrists) and feet. An experienced 
observer (DLS) who was blinded to treatment read the 
digitised radiographs using modified Larsen scores17 
after the trial ended. Use of resources was recorded 
with a modified client service receipt inventory18 
treatMent strategies
tumour necrosis factor inhibitor strategy
This had two steps: 
•	Start one tumour necrosis factor inhibitor from adalimumab, etanercept, and 
infliximab. The choice depended on current local practice
•	Switch to another tumour necrosis factor inhibitor after six months if fall in disease 
activity score for 28 joints was <1.2.
All patients also received methotrexate or another disease modifying drug. Patients 
taking more than one disease modifying drug before randomisation had this tapered 
to monotherapy. Patients taking oral prednisolone at entry continued as needed.
Disease modifying drug strategy
This had four steps: 
•	Maximise initial disease modifying drug treatment(s) 
•	Add second/third disease modifying drug
•	Start fourth/fifth disease modifying drug
•	Offer tumour necrosis factor inhibitors after six months if fall in disease activity 
score for 28 joints was <1.2. 
Disease modifying drugs were given in combination and sequentially. Patients taking 
oral prednisolone at entry continued as needed; short term oral or intramuscular 
steroids were an option with this strategy.
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 administered as self completed questionnaires retro-
spectively for the previous three month period. Costs 
(for 2010–11 in £) were assessed from a health and 
social care perspective and were multiplied by two to 
represent the six month period before each assessment.
We assessed disease activity monthly by recording 
tender and swollen joint counts (28 joints), erythrocyte 
sedimentation rates, patients’ global assessments of 
disease activity (100 mm visual analogue scale), and 
the disease activity scores for 28 joints. Withdrawals 
from treatment or the trial were also recorded monthly 
together with details of drugs and adverse events.
An anonymised electronic data capture system 
 collected clinical data except radiographs (www. 
medscinet.net).
Sample size calculation
Published data on 12 month changes in scores on the 
health assessment questionnaire in rheumatoid arthri-
tis trials of tumour necrosis factor inhibitors (mean 
baseline score 1.7; reduction after treatment of 25%; 
standard deviation of change 0.4)19 and combination 
therapy with disease modifying drugs (mean baseline 
score 1.6; reduction after treatment of 31%; standard 
deviation of change 0.6)20 gave an average standard 
deviation for changes in health assessment question-
naire scores of 0.5.
The minimal clinically important change in scores on 
the health assessment questionnaire is 0.22.21 We based 
our sample size on testing the null hypothesis of a dif-
ference of >0.22 between the two treatments. With a 
(one sided) testing level of 5%, we needed a sample size 
of 176 to achieve 90% power. We recruited 214 patients 
to allow for patients not receiving treatment or drop-
ping out when treatment had started.
randomisation
Potentially eligible patients were screened and reasons 
for non-entry recorded. Consenting patients were ran-
domised in blocks of four with allocation stratified by 
region. MedSciNet generated the allocation sequence; 
trial staff had no prior knowledge of the allocation 
sequence. There were variable delays between randomi-
sation and baseline assessments because patients 
received combination disease modifying drugs and 
tumour necrosis factor inhibitors through routine NHS 
systems.
blinding
The trial was unblinded because it used treatment spe-
cific algorithms with the adjustment of multiple drug 
doses. Patients assessed their own disability and qual-
ity of life. Radiographs were read blinded.
statistical methods
Baseline characteristics were summarised by randomi-
sation group as means and standard deviations (contin-
uous normally distributed variables), medians and 
interquartile ranges (non-normally distributed vari-
ables), and frequencies and percentages (categorical 
variables).
Randomised patients who received treatment were 
assessed on an intention to treat basis. All participants 
had complete observations at baseline. Missing data at 
follow-up was imputed regardless of the reason(s) they 
was missing. For participants with missing outcomes, 
we used the baseline outcomes and other explanatory 
covariates (treatment group, sex, age, ethnicity, region, 
and disease duration) to impute the missing data, 
assuming unobserved measurements were missing at 
random (see appendix table A).
Linear regression evaluated 12 month outcomes. 
Univariate analyses were adjusted for region (design 
variable). Multivariable analyses were adjusted for 
sex, ethnicity, age, region, and duration of disease 
and baseline scores, which all influence disability. 
Generalised estimating equations with working cor-
relations (auto-regressive with lag one) evaluated dis-
ease activity score for 28 joints and its components 
measured monthly. Treatment withdrawals and toxic-
ities were compared with Fisher’s exact tests. These 
analyses compared treatment strategies ignoring sub-
sequent treatment switches. In all analyses patients 
in the tumour necrosis factor inhibitor strategy were 
the reference group. Only the primary outcome was 
tested for non-inferiority. Other outcomes were com-
pared for evidence of superiority of one or other treat-
ment strategy.
Exploratory analyses examined good responders 
according to the European League Against Rheumatism 
(EULAR)22 with odds ratios and the development of 
remission based on disease activity scores for 28 joints23 
with log rank tests on all observed data. No imputations 
were performed for these data. These analyses also 
examined differences between patients in the disease 
modifying drug strategy who stayed taking these drugs 
or switched to tumour necrosis factor inhibitors. Finally 
complete case analyses evaluated patients who fol-
lowed the protocol and received 12 months’ treatment.
We also undertook a full economic evaluation, which 
will be reported separately.
results
Patients and treatments
Participant flow and recruitment
Between September 2008 and December 2010, we 
screened 432 patients, randomised 214, and treated 205 
(fig 1). Of these 205 treated patients, 147 (72%) com-
pleted 12 months of treatment; 16 (8%) were lost to fol-
low-up; 42 (20%) discontinued the intervention and 
were followed-up; 16 (8%) stopped treatment because 
of toxicity (10 in combined drug strategy; six in tumour 
necrosis inhibitor factor strategy); five stopped (2%) 
because of disease progression (one and four, respec-
tively); and 37 (18%) stopped for other reasons includ-
ing patients’ decisions to stop treatment (21 and 16, 
respectively).
Baseline data and numbers analysed
Demographic and disease assessments were similar in 
both groups of treated patients (Table 1). All treated 
patients were analysed.
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Treatments
Before randomisation all patients had received two dis-
ease modifying drugs (Table 1): 62 had received three; 
77 were taking combinations of two or more disease 
modifying drugs; 24 were taking prednisone (mean 
dose 4 mg/day; range 1–7 mg). The treatments used are 
given in detail in appendix table B. In the disease mod-
ifying drug strategy the main initial combination was 
methotrexate and leflunomide (62 patients). Most 
patients received two or three disease modifying drugs; 
10 received four or five drugs, though not concurrently. 
At six months, 46 patients were offered tumour necrosis 
factor inhibitors; 43 received them starting treatment at 
a mean of nine months. Steroids were given to 27 
patients. Non-trial drugs were used by 88 patients in the 
first six months and by 90 in the second six months.
In the tumour necrosis factor inhibitor strategy the 
dominant initial biologic was adalimumab (58 
patients). After six months, 16 patients received another 
tumour necrosis factor inhibitor. Steroids were given to 
19 patients. Non-trial drugs were used by 94 patients in 
the first six months and by 91 in the second six months.
Outcomes
Primary outcome
Both groups had less disability, shown by falls in their 
scores on the health assessment questionnaire. Mean 
reductions were −0.30 (95% confidence interval −0.42 to 
−0.19) with the tumour necrosis factor strategy and 
−0.45 (−0.55 to −0.34) with the disease modifying drug 
strategy. Figure 2 shows that the difference between 
groups favoured the disease modifying drug strategy. 
The figure follows the recommendations of Piaggio and 
colleagues.24 It shows unadjusted regression coeffi-
cients with 95% confidence intervals. The non-inferior-
ity margin is shown for the scores on the primary 
outcome health assessment questionnaire. The mean 
difference was −0.14 and the 95% confidence interval 
(−0.29 to 0.01) was below the prespecified non-inferior-
ity boundary of 0.22. There were no pre-defined non-in-
feriority margins for the secondary outcome measures. 
Adjustment for baseline and demographic variables did 
not change this conclusion (appendix table C).
Secondary outcomes
Both groups had improved quality of life, shown by 
increases in EQ5D-3L utility scores and SF-36 summary 
scores, and some erosive progression, shown by 
increases in Larsen scores. Difference between groups 
favoured the disease modifying drug strategy with 
EQ5D-3L scores, SF-36 physical component summary 
scores, and Larsen scores and the tumour necrosis factor 
inhibitor strategy with SF-36 mental component sum-
mary scores (fig 2). With all four outcomes, 95% confi-
dence intervals of the differences between groups 
included zero. Adjustment for baseline and demographic 
variables did not change these conclusions (appendix 
table D). Fifty eight patients withdrew from study treat-
ments; there was no difference between strategies (32 in 
disease modifying drug strategy v 26 in tumour necrosis 
factor strategy; Fisher’s exact test P=0.44).
Baseline health and social care costs were similar in 
both groups. Compared with the tumour necrosis factor 
strategy, the disease modifying drug strategy reduced 
costs for months 0–6 by a mean of −£3615 (95% confi-
dence interval −£4104 to −£3182) and for months 6–12 
by −£1930 (−£2599 to −£1301).
Disease activity fell in both groups (fig 3). Initial falls 
were greater with the tumour necrosis factor inhibitor 
strategy, but with time the differences equalised. Over 
the whole 12 months the unadjusted difference between 
groups was 0.48 (95% confidence interval 0.17 to 0.79), 
favouring the tumour necrosis factor inhibitor strategy. 
The difference was predominantly because of changes in 
the erythrocyte sedimentation rate (appendix table E).
ancillary analyses
Switching treatments
Patients in the disease modifying drug strategy who 
remaining taking disease modifying drugs (n=58) or 
switched to tumour necrosis factor inhibitors (n=46) 
had similar 12 month outcomes in all analyses. At six 
months the “switchers” had higher mean scores on the 
health assessment questionnaire (1.64 v 1.42) and dis-
ease activity scale for 28 joints (5.76 v 4.01).
Exploratory analyses using all observed data
Eighty patients had remissions (36 in disease modifying 
drug strategy, 44 in tumour necrosis factor inhibitor 
strategy) at any point in the trial. Only 30 patients 
(11 and 19, respectively) had sustained remissions. Time 
to first remission did not differ significantly between 
Tumour necrosis factor inhibitors (n=107):
  Received intervention (n=101)
    First inhibitor (n=101)
    Second inhibitor (n=16)
  Did not receive intervention (n=6):
    Patient’s decision (n=3)
    Clinician’s decision (n=3)
Intention to treat (n=101)
Completers (n=75)
Drug combinations (n=107):
  Received intervention (n=104)
    2/3 drugs (n=94)
    4/5 drugs (n=10)
    Steroids (n=30)
    Tumour necrosis factor inhibitors
      recommended/received (n=46/43)
  Did not receive intervention (n=3):
    Patient’s decision (n=3)
Lost to follow-up (n=9):
  Patient’s decision (n=1)
  Toxicity of treatment (n=4)
  Other (n=4)
Discontinued intervention (n=23):
  Disease progression (n=1)
  Patient’s decision (n=7)
  Toxicity of treatment (n=6)
  Other (n=9)
Lost to follow-up (n=7):
  Disease progression (n=1)
  Patient’s decision (n=1)
  Toxicity of treatment (n=1)
  Other (n=4)
Discontinued intervention (n=19):
  Disease progression (n=3)
  Patient’s decision (n=1)
  Toxicity of treatment (n=5)
  Other (n=10)
Assessed for eligibility (n=432)
Randomised (n=214)
Intention to treat (n=104)
Completers (n=72)
Excluded (n=218):
  Not consented (n=196)
  Ineligible (n=20)
  No data recorded (n=2)
Fig 1 | Consort flowchart of study in patients with rheumatoid arthritis randomised to 
treatment with combinations of disease modifying drugs or tumour necrosis factor inhibitors
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groups (log rank test P=0.09). More patients in the 
tumour necrosis factor inhibitor strategy, however, 
achieved early remission; after three months 16 patients 
were in remission compared with five in the disease 
modifying drug strategy.
Sixty six patients had good responses according to 
the European League Against Rheumatism at 12 months 
(37/94 in the tumour necrosis factor inhibitor strategy, 
29/92 in the disease modifying drug strategy). The odds 
ratio of achieving a good response with the disease 
modifying strategy was 0.71 (95% confidence intervals 
0.39 to 1.30) compared with the tumour necrosis factor 
inhibitor strategy.
Completer analysis
The results comparing treatments in the 147 complete 
cases (72 in disease modifying drug strategy, 75 in 
tumour necrosis factor inhibitor strategy) were similar 
to those seen in the intention to treat analysis (appen-
dix table A).
Harms
Adverse events (Table 2) were common: 28 patients had 
serious adverse events (18 with the tumour necrosis 
 factor inhibitor strategy; 10 with the disease modifying 
drugs strategy; Fisher’s exact test P=0.11). One patient 
in the tumour necrosis factor strategy died from pneu-
monia and multiple organ failure. Sixteen patients (six 
and 10, respectively) stopped treatment because of tox-
icity (Fisher’s exact test P=0.44). Overall there were 
1100 adverse events; more occurred with the disease 
modifying drug strategy (635 v 465). Infections that 
involved several body systems occurred in 54 patients 
in the tumour necrosis factor strategy and 30 patients in 
the disease modifying drug strategy.
discussion
interpretation
In patients with rheumatoid arthritis, our strategy of 
treatment with synthetic disease modifying drugs 
achieved non-inferior outcomes to the NICE approved 
strategy of treatment with tumour necrosis factor 
inhibitor over 12 months. It also cost substantially 
less. Our primary outcome—the score on the health 
assessment questionnaire—fell in both groups, indi-
cating reduced disability at the trial endpoint. The 
difference between groups favoured the disease mod-
ifying drug strategy, with 95% confidence intervals 
table 1 | baseline demographic and clinical characteristics of patients with rheumatoid 
arthritis randomised to treatment with combinations of disease modifying drugs or 
tumour necrosis factor inhibitors. Figures are means (sD) unless stated otherwise
Combination disease 
modifying drugs 
strategy (n=104)
tumour necrosis 
factor inhibitor 
strategy (n=101)
Demographic variables
Age (years) 58 (13) 57 (11)
No (%) of women/men 73/31 (70/30) 79/22 (78/22)
No (%) by ethnic group:
 White 89 (86) 92 (91)
 Black (African, Caribbean, other) 6 (6) 2 (2)
 Other 9 (9) 7 (7)
Median (IQR) duration of disease (years) 4.4 (1.6–9.9) 5.9 (2.2–13.4)
Height (m) 1.64 (0.11) 1.66 (0.09)
Weight (kg) 78 (20) 81 (17)
Median (IQR) BMI 29 (24–33) 29 (25–32)
Clinical variables
Disease activity score for 28 joints 6.2 (0.9) 6.3 (0.8)
Tender joint count 16 (7) 18 (7)
Swollen joint count 11 (6) 11 (7)
ESR (mm in first hour) 33 (26) 30 (23)
Patient global visual analogue score (mm) 68 (20) 68 (21)
Health assessment questionnaire score 1.8 (0.6) 1.9 (0.7)
Larsen score 45 (42) 38 (39)
EQ5D score 0.39 (0.31) 0.35 (0.31)
SF-36 physical component summary score 28 (7) 27 (7)
SF-36 mental component summary score 43 (12) 41 (12)
Previous disease modifying drug treatments (no of patients)
Methotrexate 98 97
Sulfasalazine 68 56
Leflunomide 27 29
Other 48 49
Three previous treatments 33 29
Combination drugs at screening 38 39
Prednisolone at screening (mean daily dose) 16 (4 mg) 8 (4 mg)
BMI=body mass index; IQR=interquartile range; ESR=erythrocyte sedimentation rate.
-0.3 -0.2 -0.1 0 0.1 0.2 0.3
Favours disease modifying
drug combinations
Non-inferiority
margin
Primary outcome measure
Health assessment questionnaire
Favours tumour necrosis
factor inhibitors
0.3 0.2 0.1 0 -0.1 -0.2 -0.3
Secondary outcome measures
EQ5D-3L
3 25 4 1 0 -1 -2 -3 -4 -5
SF-36 physical component summary score
3 25 4 1 0 -1 -2 -3 -4 -5
-2 -1 0 1 2
Larsen score
SF-36 mental component summary score
Fig 2 | Observed treatment differences for primary and 
secondary outcome measures in study in patients with 
rheumatoid arthritis randomised to treatment with 
combinations of disease modifying drugs or tumour 
necrosis factor inhibitors. scales and direction of change 
for different outcome measures vary: health assessment 
questionnaire ranges from 0–3, higher scores are worse, 
and positive differences favour tumour necrosis factor 
strategy; eQ5D-3l ranges from 0–1, higher scores are 
better, and negative differences favour tumour necrosis 
factor strategy; sF-36 physical component score and 
mental component score range from 0–100, higher scores 
are better, and negative differences favours tumour 
necrosis factor strategy; larsen score ranges from 0–200, 
higher scores are worse, and positive differences favours 
tumour necrosis factor strategy
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within the prespecified boundary of non-inferiority. 
Both strategies improved quality of life similarly and 
resulted in minimal erosive progression. The tumour 
necrosis factor inhibitor strategy cost an additional 
average £5545 (€7570, $8586) per patient. Its main 
benefit was rapid falls in disease activity and more 
early remissions. As synthetic disease modifying 
drugs are “slow acting” agents,25 this difference is not 
surprising. Patients who did not respond to six 
months of treatment with disease modifying drugs 
and who switched to tumour necrosis factor inhibi-
tors were not disadvantaged.
Over 12 months, health and social care costs were 
£5545 less in patients who were treated with the com-
bined drug strategy. These reduced costs were associated 
with reduced scores on the health assessment question-
naire, which have immediate economic benefits.26 27 Our 
results support using the combined drug strategy for 
12  months. Longer term observational and detailed 
 economic modelling studies are needed to show whether 
this approach has any enduring benefits.28 29
Tumour necrosis factor inhibitors have many advan-
tages. Their innovative nature, rapid effects, and ease of 
use attract patients and clinicians. Their defined mech-
anism of action contrasts with the uncertainties about 
the molecular effects of drugs like methotrexate. Com-
binations of lower cost synthetic disease modifying 
drugs, however, are relevant for advanced health econ-
omies and might be even more relevant in health econ-
omies where biologics are unaffordable.
generalisability
The patients in our trial had diverse ethnicities and 
deprivation levels and were seen in routine practice set-
tings in geographically dispersed centres in England. 
We focused on patient centred outcomes, which are cru-
cial for people with arthritis. Levels of disease activity 
replicated levels in national and international regis-
ters30 31 before and during treatment.
limitations
Our trial had several limitations. Firstly, many eligible 
patients did not participate, mainly because they did not 
consent. Although non-consenting patients could have 
responded differently to participants,32 participation 
levels replicated other English grant funded trials in 
rheumatoid arthritis20 and recent tumour necrosis factor 
inhibitors trials.33 Non-participation is likely to reflect 
patients’ concerns about all intensive treatments34 and 
our cautiously worded patient information sheet.35
Secondly, disease modifying drugs regimens varied 
because standardisation was impossible in this context. 
Thirdly, few trials in rheumatoid arthritis use the health 
assessment questionnaire as their primary outcome mea-
sure. It was relevant in our trial because it measures 
changes important to patients, is sensitive to improve-
ments with all tested treatments,15 16 and helps NICE to 
determine treatment benefits. Scores on the health assess-
ment questionnaire change less in those with late rheuma-
toid arthritis,36 but both groups had clinically important 
improvements, and the durations of disease in our 
patients were comparable with those in pivotal biologic 
trials.19 37 38 Although minimally important differences in 
scores might be less than 0.22 in routine practice,39 this 
lower difference would not change our conclusions.
Fourthly, our trial was un-blinded because blinding 
is impractical when many different treatments are used. 
The primary outcome, however, was self completed by 
patients and not directly influenced by clinicians. 
Fifthly, our trial lasted only 12 months because when it 
was designed longer delays in assessing biologic treat-
ments raised ethical concerns.
Finally, the effects of withdrawal and switching treat-
ments need careful consideration. Only a few patients 
(16/205, 8%) were lost to follow-up and required the impu-
tation of missing data. As the complete case analysis gave 
similar findings to the intention to treat  analysis, it seems 
unlikely that withdrawals influenced our conclusions. 
Comparable numbers of patients withdrew from both 
trial arms, suggesting withdrawals were unlikely to be 
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Fig 3 | Changes in mean (se) Das28 scores (intention to 
treat analysis) in patients with rheumatoid arthritis 
randomised to treatment with combinations of disease 
modifying drugs or tumour necrosis factor inhibitors
table 2 | adverse events by body system in patients 
with rheumatoid arthritis randomised to treatment with 
combinations of disease modifying drugs or tumour 
necrosis factor inhibitors
body system*
Combination disease 
modifying drugs 
strategy (n=104)
tumour necrosis 
factor inhibitor 
strategy (n=101)
serious all serious all
Cardiovascular 2 22 2 17
Digestive 0 148 4 60
Ear, nose, throat 0 88 1 76
Endocrine/metabolic 0 7 1 7
Genitourinary 3 28 1 27
Haematological 1 25 1 10
Mental 0 24 0 15
Musculoskeletal 0 104 1 94
Nervous system 1 61 2 41
Ophthalmological 0 12 0 5
Respiratory 3 59 3 66
Skin 0 57 2 47
Total 635 465
*As infections involved several different body systems, they could not be 
incorporated within table. In combination disease modifying drugs 
strategy, five serious adverse events involved an infection and 30 patients 
had infection. In tumour necrosis factor inhibitor strategy, seven serious 
adverse events involved an infection and 54 patients had infection.
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 influenced by the treatment strategies. Overall withdrawal 
rates were similar to those in comparable rheumatoid 
arthritis strategy trials involving biologics and disease 
modifying drugs.40–43 The frequencies with which patients 
discontinued tumour necrosis factor inhibitors were com-
parable with UK national registry data of routine practice 
results.44 The evidence suggests withdrawals in our trial 
were unlikely to have influenced our main conclusions.
Overall evidence
In early rheumatoid arthritis three head-to-head trials 
have shown that combinations of disease modifying 
drugs achieve similar benefits to tumour necrosis fac-
tor inhibitors.40–42 RACAT, the only other trial in estab-
lished active rheumatoid arthritis,43 showed that 
triple therapy (methotrexate, sulfasalazine, and 
hydroxychloroquine) achieved similar benefits to 
etanercept plus methotrexate in incomplete metho-
trexate responders treated for 12 months. Our trial and 
RACAT had comparable results, despite differences in 
patients and trial design. They highlight the role of 
head-to-head trials against effective conventional 
comparators to evaluate expensive treatments.45 
Although toxicity remains a potential concern with 
combined disease modifying drugs because single tri-
als like ours cannot fully assess risks, such combina-
tions have been used for many years without evidence 
of major toxicity.10 11
The current trail questions the status quo of use of 
biologics in patients with active rheumatoid arthritis in 
whom methotrexate does not achieve the required 
response. In these patients the clinical and economic 
evidence from our trial supports preferentially starting 
combinations of synthetic disease modifying drugs. 
We  also believe that modernising biologic treatment 
regimens for rheumatoid arthritis requires more strat-
egy trials. Increasing efficacy is important, and optimis-
ing cost effectiveness is crucial. Options include giving 
biologics to patients with rheumatoid arthritis who are 
likely to respond to specific agents,46 47 discontinuing 
biologics when patients do not fully respond, and 
tapering treatment when patients achieve sustained 
remissions.48
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